Tau
45 programs · 43 companies
Programs
45
Companies
43
Active Trials
30
Targeting Tau
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| NVO-9087 | Novo Nordisk | Phase 1/2 | LNCF | |
| Tezecilimab | Takeda | NDA/BLA | Parkinson'sMigraine | |
| TAK-8262 | Takeda | NDA/BLA | Hemophilia A | |
| TER-5062 | Terns | Phase 2/3 | Wet AMD | |
| Elraderotide | Chugai | Phase 1/2 | AngelmanParkinson's | |
| Gozebrutinib | Tempus AI | Approved | CRCWilms | |
| ONC-2103 | Oncopeptides | Phase 1/2 | CTCLAngelman | |
| MAY-IIT-513 | Mayo Clinic | Phase 2/3 | Schizophrenia | |
| Motatenlimab | Sutro Bio | Preclinical | DravetOvarian Ca | |
| LRM-3193 | Larimar | Phase 2 | CeliacUC | |
| Olpavorutinib | Replimune | Phase 2 | Pancreatic CaPSP | |
| ALG-2734 | Aligos | Approved | MSGIST | |
| Datoglumide | Adicet (Regeneron) | Phase 2 | Bladder Ca | |
| Datolucimab | Tonix Pharma | Phase 1/2 | PsoriasisCKD | |
| Capiratamab | Reata Pharma (Biogen) | Phase 1 | Atopic Derm | |
| PMC-7054 | PharmaCyte Biotech | Phase 2 | CRC | |
| G1-2036 | G1 Therapeutics (Licella) | Phase 3 | LGS | |
| Elralucimab | Bioventus | Phase 1 | NMOSDT2D | |
| KUM-1252 | Kumquat Bio | Preclinical | MelanomaCervical Ca | |
| Tixatuximab | Alexion (AZN) | Phase 2 | GAOvarian Ca | |
| ORC-1969 | Orchard (Kyowa Kirin) | Phase 1 | DravetHS | |
| GW-1242 | GW Pharma (Jazz) | Phase 1/2 | PBCHuntington's | |
| MED-3942 | Medivation (Pfizer) | Phase 2 | NSCLC | |
| 225-7610 | Sirnaomics | NDA/BLA | Dravet | |
| Polatinib | Quanta Ther | Phase 2 | MCCRett | |
| Pemitenlimab | Valo Health | Phase 3 | NSCLCUrothelial Ca | |
| ENC-8622 | Encoded Ther | Phase 3 | AngelmanUrothelial Ca | |
| IVE-9723 | Iveric (Astellas) | Phase 3 | PNHIPF | |
| Ivoratamab | Design Ther | Phase 2/3 | ADPKD | |
| Tixaratamab | Abclon | Preclinical | MigraineOCD | |
| STA-5151 | Strides Pharma | Phase 1/2 | Pompe | |
| 219-5261 | Shanghai Fosun | Phase 3 | Ovarian CaADHD | |
| Gozetenlimab | Shanghai Fosun | NDA/BLA | SCD | |
| IMV-3202 | Immunovant | Approved | Parkinson'sPBC | |
| VEC-6874 | Vectura (PMI) | Phase 2/3 | FL | |
| Mavusertib | BTG (Boston Sci) | Approved | Celiac | |
| Tixacapivasertib | Noxopharm | Approved | Heart FailureMG | |
| 414-2764 | TaiMed Bio | Phase 2/3 | MyelofibrosisPompe | |
| TES-326 | Tessa Therapeutics | Approved | HNSCCMeso | |
| Ivozasiran | Orient Pharma | Phase 1/2 | ETEpilepsy | |
| LUP-4095 | Lupin Limited | Phase 2/3 | Endometrial Ca | |
| HET-1500 | Hetero Drugs | Phase 2/3 | PBC | |
| Liranesiran | Agilent Technologies | Phase 3 | MCC | |
| WST-2406 | West Pharma | Phase 2 | Thymoma | |
| KRK-5622 | KRKA | Phase 2 | Ovarian CaNB |